About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Zydus Cadila Receives FDA Approval for Marketing Pioglitazone in US

by Kathy Jones on February 15, 2013 at 9:23 PM
Font : A-A+

 Zydus Cadila Receives FDA Approval for Marketing Pioglitazone in US

Indian pharmaceutical firm Zydus Cadila revealed that it has received the final approval from the US Food and Drug Administration to market its anti-diabetic drug, Pioglitazone HCI, in the American market.

Zydus announced that it has received approval to market Pioglitazone HCI tablets in 15 mg, 30 mg and 45 mg strengths. The company added that sales for Pioglitazone HCI tablets was estimated at $2 billion in 2012, according to data from IMS.

Advertisement

The company has so far filed over 170 Abbreviated New Drug Applications (ANDA) since 2003-04 and has so far received 75 approvals, including for the sale of oral tablets of Ultracet.


Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
Long-Term Glycemic Control - A Better Measure of COVID-19 Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.


Recommended Reading
Diabetes - Foot Care
Valuable information on diabetic foot care, treatment and prevention....
Diabetes Diet Plan
Diet plays a significant role in controlling diabetes. Most cases of diabetes are preventable with ....
Diabetes and Exercise
Regular exercise especially in type II diabetes not only helps reduce the sugar but also reduces ......

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use